332 related articles for article (PubMed ID: 30765202)
21. Enteric nematodes and the path to up-regulation of type 2 cytokines IL-4 and IL-13.
Shea-Donohue T; Sun R; Bohl JA; McLean LP; Zhao A
Cytokine; 2015 Sep; 75(1):62-7. PubMed ID: 26188364
[TBL] [Abstract][Full Text] [Related]
22. Exploring the role of interleukin-22 in neurological and autoimmune disorders.
Xin N; Namaka MP; Dou C; Zhang Y
Int Immunopharmacol; 2015 Oct; 28(2):1076-83. PubMed ID: 26311525
[TBL] [Abstract][Full Text] [Related]
23. Unregulated IL-23/IL-17 immune response in autoimmune diseases.
Costa VS; Mattana TC; da Silva ME
Diabetes Res Clin Pract; 2010 Jun; 88(3):222-6. PubMed ID: 20392505
[TBL] [Abstract][Full Text] [Related]
24. IL-6: regulator of Treg/Th17 balance.
Kimura A; Kishimoto T
Eur J Immunol; 2010 Jul; 40(7):1830-5. PubMed ID: 20583029
[TBL] [Abstract][Full Text] [Related]
25. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 23 and autoimmune diseases: current and possible future therapies.
Abdo AIK; Tye GJ
Inflamm Res; 2020 May; 69(5):463-480. PubMed ID: 32215665
[TBL] [Abstract][Full Text] [Related]
27. Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review.
Lee KH; Ahn BS; Cha D; Jang WW; Choi E; Park S; Park JH; Oh J; Jung DE; Park H; Park JH; Suh Y; Jin D; Lee S; Jang YH; Yoon T; Park MK; Seong Y; Pyo J; Yang S; Kwon Y; Jung H; Lim CK; Hong JB; Park Y; Choi E; Shin JI; Kronbichler A
Autoimmun Rev; 2020 Mar; 19(3):102469. PubMed ID: 31918027
[TBL] [Abstract][Full Text] [Related]
28. Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.
Ghali JR; Holdsworth SR; Kitching AR
Curr Med Chem; 2015; 22(38):4341-65. PubMed ID: 26521930
[TBL] [Abstract][Full Text] [Related]
29. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W; Patel DD; Dryja T; Wright AM; Koroleva I; Bruin G; Antoni C; Draelos Z; Gold MH; ; Durez P; Tak PP; Gomez-Reino JJ; ; Foster CS; Kim RY; Samson CM; Falk NS; Chu DS; Callanan D; Nguyen QD; ; Rose K; Haider A; Di Padova F
Sci Transl Med; 2010 Oct; 2(52):52ra72. PubMed ID: 20926833
[TBL] [Abstract][Full Text] [Related]
30. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
Yamagata T; Skepner J; Yang J
Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
[TBL] [Abstract][Full Text] [Related]
31. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
Konya C; Paz Z; Apostolidis SA; Tsokos GC
Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
[TBL] [Abstract][Full Text] [Related]
32. Insights into IL-37, the role in autoimmune diseases.
Xu WD; Zhao Y; Liu Y
Autoimmun Rev; 2015 Dec; 14(12):1170-5. PubMed ID: 26264940
[TBL] [Abstract][Full Text] [Related]
33. Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice.
Yang GX; Sun Y; Tsuneyama K; Zhang W; Leung PS; He XS; Ansari AA; Bowlus C; Ridgway WM; Gershwin ME
Clin Exp Immunol; 2016 Aug; 185(2):154-64. PubMed ID: 27148790
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
35. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
Williams RO; Paleolog E; Feldmann M
Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of IL-27 in multiple sclerosis?
Fitzgerald DC; Rostami A
Expert Opin Biol Ther; 2009 Feb; 9(2):149-60. PubMed ID: 19236245
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-27 mediates inflammation during chronic disease.
Wynick C; Petes C; Gee K
J Interferon Cytokine Res; 2014 Oct; 34(10):741-9. PubMed ID: 24797503
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
39. Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance.
Li Q; Shan Q; Sang X; Zhu R; Chen X; Cao G
Am J Chin Med; 2019; 47(1):177-201. PubMed ID: 30612460
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
